wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q33633424-05838F84-DAAA-486C-BD83-E36F5D2A5FD7
Q33633424-05838F84-DAAA-486C-BD83-E36F5D2A5FD7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33633424-05838F84-DAAA-486C-BD83-E36F5D2A5FD7
Oral anticancer drugs: how limited dosing options and dose reductions may affect outcomes in comparative trials and efficacy in patients.
P2860
Q33633424-05838F84-DAAA-486C-BD83-E36F5D2A5FD7
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33633424-05838F84-DAAA-486C-BD83-E36F5D2A5FD7
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
4348b9bfecc1351499192d9273e048bd3f660e13
P2860
A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies.